FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPI	OMB APPROVAL								
	OMB Number:	3235-0287								
	Estimated average b	urden								
- 1	hours per response:	0.5								

					- 01	Jeen	011 30(11) 0	JI LIIC	HIV	Collicit	20111	pany Act	01 13	740							
Name and Address of Reporting Person* Miller Redonda				2. Issuer Name and Ticker or Trading Symbol Adagio Therapeutics, Inc. [ADGI]									(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Willer Redolida																X Director		10% Owner		ner	
(Last)	`	irst) RAPEUTICS, II	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/19/2021								Officer below)	(give title		Other (s below)	pecify			
1601 TRAPELO ROAD, SUITE 178				4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line)						
(Street)																X Form filed by One Reporting Person					
WALTH	AM M	[A	02451													Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																		
		Tab	le I - Nor	n-Deriv	ative	e Se	curities	s Ac	qu	ired, D	isp	osed o	f, o	r Bene	eficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date		Date	Transaction Code (Instr. 5		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F Reported	es Forn ially (D) o Following (I) (II		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
										Code		Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				,iii3ti. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution of if any (Month/Day	Date, T	ransa ode (I					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly OF	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					·odo	v	(4)	(5)	Dat	ite	Ex	epiration	Title	N C	Amount or Number of						

Explanation of Responses:

\$20.07

1. One third (1/3) of the option shall vest on November 19, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 19th day of each month, subject to the Reporting Person's continuous service on each vesting date.

(1)

Remarks:

Stock Option

(Right to Buy)

/s/ Dorothy Vinsky, Attorney-

62,605

\$0.00

11/23/2021

62,605

D

in-Fact

Common

Stock

11/18/2031

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

11/19/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

62,605